GE Hitachi wins contract to develop US supply of medical isotope
21 January 2010
GE Hitachi Nuclear Energy (GEH) has been selected by the US
Department of Energy’s National Nuclear Security Administration (NNSA)
to help develop a US supply of a radioisotope used in more than 20
million diagnostic medical procedures in the United States each year.
NNSA has chosen GEH to help create a reliable US supply of
molybdenum-99 without the use of highly enriched uranium (HEU) to
respond to a shortage from repeated, unplanned outages at facilities
where it currently is produced.
Molybdenum-99 is the precursor of technetium-99m, the radioisotope
most widely used in nuclear medicine diagnostic procedures, including
the detection of cancer, heart disease and thyroid disease, along with
the study of brain and kidney function and the imaging of stress
fractures, according to the Society of Nuclear Medicine.
GEH’s new technology does not rely on the fissioning of HEU,
advancing a key non-proliferation initiative for the United States.
Because GEH’s technology can be used in existing nuclear reactors, the
need to build new reactors dedicated to isotope production is reduced.
“NNSA is committed to supporting technology that offers a new path
forward for the creation of a reliable, domestic supply of molybdenum-99
without the use of HEU,” said NNSA Administrator Thomas D'Agostino.
“This pragmatic approach addresses a critical U.S. medical community
need while supporting President Obama's goal of reducing the risk posed
by global use of HEU.”
Deploying GEH’s isotope production technology potentially could meet
at least 50 percent of the United States’ projected supply needs for
molybdenum-99/technetium-99m to help ensure patient access to vital
medical diagnostic procedures. GEH will conduct research and development
to confirm its technology at commercial scale and determine the
infrastructure and logistics needed to support commercial operation.
“We are seeking some short-term solutions that have long-term
potential, and the GEH technical solution provides a path forward that
is quite attractive to meet both these needs,” said Robert Atcher, MD,
PhD, past president of the Society of Nuclear Medicine, who evaluated
GEH’s isotope technology.
With a half-life of only 66 hours, molybdenum-99 must be delivered to
hospitals on a frequent and consistent basis. Molybdenum-99 decays into
technetium-99m, the radioisotope most widely used in common diagnostic
procedures. It is used in about 80% of all nuclear medicine procedures,
including evaluation of the heart, kidneys, lungs, liver, spleen, bones
and blood flow.
“We are pleased to work with NNSA to address this isotope challenge,”
said Chris Monetta, GEH Senior Vice President, Advanced Programs,
Nuclear Fuel Cycle. “Our technical approach holds great promise for
helping to ensure that a safe and reliable supply of molybdenum is
available to help doctors care for their patients.”
GE has more than a half-century of experience in providing isotopes
for medical and industrial applications. The GE Test Reactor (GETR),
which began operating in 1959, was the first commercially licensed test
reactor in the world. GE developed many of the standards and
specifications used in the isotope market today. As a result of work
performed at GETR, GE produced 30 isotopes, including molybdenum-99, for
medical and industrial uses.
GEH recently announced a landmark agreement with Exelon Generation
Company for a pilot project to meet growing demand for cobalt-60, a
radioisotope used for treating cancer and other biomedical applications.